D-Ala2GIP facilitated synaptic plasticity and reduces plaque load in aged wild type mice and in an Alzheimer's disease mouse model

Journal of Alzheimer's Disease

Volumn 35, Issue 2, 2013, Pages 267-283

  Faivre, Emilie ^a   Hölscher, Christian ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

Growth factor; incretins; insulin; neuroprotection

Indexed keywords

DEXTRO ALANINE 2 GLUCOSE DEPENDENT INSULINOTROPIC POLYPEPTIDE; GLUCOSE; INSULIN; NEUROPROTECTIVE AGENT; UNCLASSIFIED DRUG; AMYLOID PRECURSOR PROTEIN; GASTRIC INHIBITORY POLYPEPTIDE; GLUCOSE DEPENDENT INSULINOTROPIC POLYPEPTIDE, ALA(2); GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE, ALA(2)-; PRESENILIN 1;

AGE; ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL MODEL; ARTICLE; BODY WEIGHT; BRAIN CORTEX; CONTROLLED STUDY; GLUCOSE BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; MALE; MAZE TEST; MICROGLIA; MOUSE; NERVE CELL PLASTICITY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOASSAY; WILD TYPE; ANIMAL; BLOOD; C57BL MOUSE; DISEASE COURSE; DRUG EFFECT; ENCEPHALITIS; GENETICS; HIPPOCAMPAL CA1 REGION; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; LEARNING; LONG TERM POTENTIATION; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOMOTOR PERFORMANCE; RECOGNITION; SYNAPSE; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; CA1 REGION, HIPPOCAMPAL; DISEASE PROGRESSION; ENCEPHALITIS; GASTRIC INHIBITORY POLYPEPTIDE; HUMANS; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRAPERITONEAL; INSULIN; LEARNING; LONG-TERM POTENTIATION; MALE; MAZE LEARNING; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEURONAL PLASTICITY; PLAQUE, AMYLOID; PRESENILIN-1; PSYCHOMOTOR PERFORMANCE; RECOGNITION (PSYCHOLOGY); SYNAPSES;

EID: 84877115450     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-121888     Document Type: Article

References (52)

1. Alzheimer A (1907) Ueber eine eigenartige Erkrankung der Hirnrinde. Zeitschrift fuer Psychiatrie 64, 146-149
2. Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82, 239-259
3. Alzheimer A, Stelzmann RA, Schnitzlein HN, Murtagh FR (1995) An English translation of Alzheimer's 1907 paper, "Uber eine eigenartige Erkankung der Hirnrinde". Clin Anat 8, 429-431
4. Whitehouse P (1997) Genesis of Alzheimer's disease. Neurology 48, S2-S7
5. Weiner MF (1997) Alzheimer's disease: Diagnosis and treatment. Harv Rev Psychiatry 4, 306-316
6. Holscher C (2010) The role of GLP-1 in neuronal activity and neurodegeneration. Vitam Horm 84, 331-354
7. Watson GS, Craft S (2004) Modulation of memory by insulin and glucose: Neuropsychological observations in Alzheimer's disease. Eur J Pharmacol 490, 97-113
8. Craft S (2005) Insulin resistance syndrome and Alzheimer's disease: Age-And obesity-related effects on memory, amyloid, and inflammation. Neurobiol Aging 26(Suppl 1), 65-69
9. Holscher C (2011) Diabetes as a risk factor for Alzheimer's disease: Insulin signalling impairment in the brain as an alternative model of Alzheimer's disease. Biochem Soc Trans 39, 891-897
10. Carro E, Torres-Aleman I (2004) The role of insulin and insulin-like growth factor I in the molecular and cellular mechanisms underlying the pathology of Alzheimer's disease. Eur J Pharmacol 490, 127-133
11. Lester-Coll N, Rivera EJ, Soscia SJ, Doiron K, Wands JR, de la Monte SM (2006) Intracerebral streptozotocin model of type 3 diabetes: Relevance to sporadic Alzheimer's disease. J Alzheimers Dis 9, 13-33
12. Moloney AM, Griffin RJ, Timmons S, O'Connor R, Ravid R, O'Neill C (2010) Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol Aging 31, 224-243
13. Talbot K, Wang HY, Kazi H, Han LY, Bakshi KP, Stucky A, Fuino RL, Kawaguchi KR, Samoyedny AJ, Wilson RS, Arvanitakis Z, Schneider JA, Wolf BA, Bennett DA, Trojanowski JQ, Arnold SE (2012) Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest 122, 1316-1338
14. Zhao WQ, De Felice FG, Fernandez S, Chen H, Lambert MP, Quon MJ, Krafft GA, Klein WL (2008) Amyloid beta oligomers induce impairment of neuronal insulin receptors. FASEB J 22, 246-260
15. Xie L, Helmerhorst E, Taddei K, Plewright B, Van BW, Martins R (2002) Alzheimer's beta-Amyloid peptides compete for insulin binding to the insulin receptor. J Neurosci 22, RC221
16. Lebovitz HE, Banerji MA (2004) Treatment of insulin resistance in diabetes mellitus. Eur J Pharmacol 490, 135-146
17. Havrankova J, Brownstein M, Roth J (1981) Insulin and insulin receptors in rodent brain. Diabetologia 20 (Suppl), 268-273
18. Hoyer S (2004) Glucose metabolism and insulin receptor signal transduction in Alzheimer disease. Eur J Pharmacol 490, 115-125
19. Craft S (2007) Insulin resistance and Alzheimer's disease pathogenesis: Potential mechanisms and implications for treatment. Curr Alzheimer Res 4, 147-152
20. Gasparini L, Xu H (2003) Potential roles of insulin and IGF-1 in Alzheimer's disease. Trends Neurosci 26, 404-406
21. Carro E, Torres AI (2004) The role of insulin and insulinlike growth factor I in the molecular and cellular mechanisms underlying the pathology of Alzheimer's disease. Eur J Pharmacol 490, 127-133
22. Yip RG, Wolfe MM (2000) GIP biology and fat metabolism. Life Sci 66, 91-103
23. Usdin TB, Mezey E, Button DC, Brownstein MJ, Bonner TI (1993) Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain. Endocrinology 133, 2861-2870
24. Nyberg J, Anderson MF, Meister B, Alborn AM, Strom AK, Brederlau A, Illerskog AC, Nilsson O, Kieffer TJ, Hietala MA, Ricksten A, Eriksson PS (2005) Glucose-dependent insulinotropic polypeptide is expressed in adult hippocampus and induces progenitor cell proliferation. J Neurosci 25, 1816-1825
25. Nyberg J, Jacobsson C, Anderson MF, Eriksson PS (2007) Immunohistochemical distribution of glucose-dependent insulinotropic polypeptide in the adult rat brain. J Neurosci Res 85, 2099-2119
26. Holscher C (2010) Incretin analogues that have been developed to treat type 2 diabetes hold promise as a novel treatment strategy for Alzheimer's disease. RecentPatCNSDrug Discov 5, 109-117
27. Gault VA, Holscher C (2008) Protease-resistant glucosedependent insulinotropic polypeptide agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by Beta-Amyloid. J Neurophysiol 99, 1590-1595
28. Figueiredo CP, Pamplona FA, Mazzuco TL, Aguiar AS Jr, Walz R, Prediger RD (2010) Role of the glucose-dependent insulinotropic polypeptide and its receptor in the central nervous system: Therapeutic potential in neurological diseases. Behav Pharmacol 21, 394-408
29. Buhren BA, Gasis M, Thorens B, MullerHW, Bosse F (2009) Glucose-dependent insulinotropic polypeptide (GIP) and its receptor (GIPR): Cellular localization, lesion-Affected expression, and impaired regenerative axonal growth. J Neurosci Res 87, 1858-1870
30. Faivre E, Hamilton A, Holscher C (2012) Effects of acute and chronic administration of GIP analogues on cognition, synaptic plasticity and neurogenesis in mice. Eur J Pharmacol 674, 294-306
31. Porter DW, Irwin N, Flatt PR, Holscher C, Gault VA (2010) Prolonged GIP receptor activation improves cognitive function, hippocampal synaptic plasticity and glucose homeostasis in high-fat fed mice. Eur J Pharmacol 650, 688-693
32. Gault VA, O'Harte FP, Flatt PR (2003) Glucose-dependent insulinotropic polypeptide (GIP): Anti-diabetic and antiobesity potential? Neuropeptides 37, 253-263
33. Gengler S, McClean P, McCurtin R, Gault V, Holscher C (2012) Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice. Neurobiol Aging 33, 265-276
34. Abbas T, Faivre E, Hölscher C (2009) Impairment of synaptic plasticity and memory formation in GLP-1 receptorKOmice: Interaction between type 2 diabetes and Alzheimer's disease. Behav Brain Res 205, 265-271
35. Faivre E, Gault VA, Thorens B, Holscher C (2011) Glucosedependent insulinotropic polypeptide receptor knockout mice are impaired in learning, synaptic plasticity, and neurogenesis. J Neurophysiol 105, 1574-1580
36. Bondolfi L, Calhoun M, Ermini F, Kuhn HG, Wiederhold KH, Walker L, Staufenbiel M, Jucker M (2002) Amyloidassociated neuron loss and gliogenesis in the neocortex of amyloid precursor protein transgenic mice. J Neurosci 22, 515-522
37. Paresce D, Chung H, Maxfield F (1997) Slow degradation of aggregates of the Alzheimer's disease amyloid beta-protein by microglial cells. J Biol Chem 14, 29390-29397
38. Radde R, Bolmont T, Kaeser SA, Coomaraswamy J, Lindau D, Stoltze L, Calhoun ME, Jaggi F, Wolburg H, Gengler S, Haass C, Ghetti B, Czech C, Holscher C, Mathews PM, Jucker M (2006) Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep 7, 940-946
39. Wilcock DM, Gordon MN, Morgan D (2006) Quantification of cerebral amyloid angiopathy and parenchymal amyloid plaques with Congo red histochemical stain. Nat Protoc 1, 1591-1595
40. Luchsinger JA, Tang MX, Shea S, Mayeux R (2004) Hyperinsulinemia and risk of Alzheimer disease. Neurology 63, 1187-1192
41. Messier C (2004) Glucose improvement of memory: A review. Eur J Pharmacol 490, 33-57
42. Mody N, Agouni A, McIlroy GD, Platt B, Delibegovic M (2011) Susceptibility to diet-induced obesity and glucose intolerance in the APP (SWE)/PSEN1 (A246E) mouse model of Alzheimer's disease is associated with increased brain levels of protein tyrosine phosphatase 1B (PTP1B) and retinol-binding protein 4 (RBP4), and basal phosphorylation of S6 ribosomal protein. Diabetologia 54, 2143-2151
43. Lacor PN, Buniel MC, Chang L, Fernandez SJ, Gong Y, Viola KL, LambertMP,Velasco PT, Bigio EH, Finch CE, Krafft GA, Klein WL (2004) Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J Neurosci 24, 10191-10200
44. LaFerla FM, Oddo S (2005) Alzheimer's disease: Abeta, tau and synaptic dysfunction. Trends Mol Med 11, 170-176
45. Lukiw WJ, Bazan NG (2000) Neuroinflammatory signaling upregulation in Alzheimer's disease. Neurochem Res 25, 1173-1184
46. Aisen PS, Davis KL (1994) Inflammatory mechanisms in Alzheimer's disease: Implications for therapy. Am J Psychiatry 151, 1105-1113
47. Greig NH, Mattson MP, Perry T, Chan SL, Giordano T, Sambamurti K, Rogers JT, Ovadia H, Lahiri DK (2004) New therapeutic strategies and drug candidates for neurodegenerative diseases: P53 and TNF-inhibitors, and GLP-1 receptor agonists. Ann N Y Acad Sci 1035, 290-315
48. Lee YJ, Han SB,NamSY,OhKW, Hong JT (2010) Inflammation and Alzheimer's disease. Arch Pharm Res 33, 1539-1556
49. Holmes C, Cunningham C, Zotova E, Culliford D, Perry VH (2011) Proinflammatory cytokines, sickness behavior, and Alzheimer disease. Neurology 77, 212-218
50. Blurton-Jones M, Kitazawa M, Martinez-Coria H, Castello NA, Muller FJ, Loring JF, Yamasaki TR, Poon WW, Green KN, Laferla FM (2009) Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. Proc Natl Acad Sci U S A 106, 13594-13599
51. Aisen PS (2002) The potential of anti-inflammatory drugs for the treatment of Alzheimer's disease. Lancet Neurol 1, 279-284
52. Cole GM, Morihara T, Lim GP, Yang F, Begum A, Frautschy SA (2004) NSAID and antioxidant prevention of Alzheimer's disease: Lessons from in vitro and animal models. Ann N Y Acad Sci 1035, 68-84